Abstract 10P
Background
Multi-gene expression tests have been widely accepted as risk-prediction tools in early-stage HR-positive and HER2-negative (HR+/HER2-) breast cancer (EBC) after surgery. This study compared the performance of the 28-gene panel that developed from the Asian breast cancer population with the 70-gene panel in Chinese women with EBC.
Methods
Pts with EBC, previously undergone 70-gene testing after primary surgery from Jan 2019 to Oct 2022 were enrolled. FFPE of primary breast tumors were collected for 28-gene testing. Clinicopathological risk factors such as diagnosed age ≤40y, ≥T2, N1, LVI positive, grade III, Ki-67≥ 20% were included in the final analyses. Pts with clinicopathological risk factors ≥2 were clinical high-risk (n=48); others were low-risk (n=51).
Results
A total of 99 Chinese pts with EBC (pT1-2N0-1 or pT3N0M0) were enrolled in this study, with a median diagnosed age of 52 years (29-74 years). The median follow-up period was 38 months, and the last follow-up date was June 20, 2023. Two pts were lost to follow-up, but none recurred or died. The 28-gene and 70-gene panels detected high-risk pts (26% vs. 34%) and low-risk (73% vs. 65%), respectively. The overall agreement of the two tests was 72% (71/99). In addition, the 28-gene panel showed higher consistency with clinical-risk prediction than the 70-gene panel (Kappa: 0.51 vs. 0.39). Among them, the consistency of the 28-gene panel and 70-gene panel with the low clinical-risk prediction was 98% (50/51) and 84% (43/51), respectively; the high-risk prediction was 47% (25/48) and 54% (26/48), respectively. Table: 10P
Risk prediction comparison of 28-gene and 70-gene panels
| Characteristic | 28-gene (%) | Kappa | 70-gene (%) | Kappa | |||
| High-risk | Low-risk | High-risk | Low-risk | ||||
| Clinical | High-risk | 25(25) | 23(23) | 0.51 | 26(26) | 22(22) | 0.39 |
| Low-risk | 1(1) | 50(51) | P<0.001 | 8(8) | 43(43) | P<0.001 | |
| Total | 26(26) | 73(74) | 99(100) | 34(34) | 65(66) | 99(100) |
Conclusions
The performance of the 28-gene panel in risk prediction of EBC was comparable with the 70-gene panel. The 28-gene panel could identify a more low-risk population in Chinese breast cancer pts. An enlarged sample size and longer follow-up for clinical outcomes will further confirm our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key Research and Development Program of China (2019YFE0196500).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract